Loading...
The efficacy of monthly injectable long-acting cabotegravir plus rilpivirine (LA CAB+RPV) for HIV infection was recently demonstrated in the ATLAS (N Engl J Med 2020; 382:1112) and FLAIR (N Engl J Med 2020; 382:1124) studies. Based on LATTE-2 study data (Lancet 2017 Jul 24; [e-pub]), investigators conducted an industry-funded study of LA CAB+RPV every 4 weeks versus every 8 weeks for maintaining viral suppression in persons with HIV (PWH). Participants comprised PWH who had achieved viral suppression on an oral standard-of-care antiretroviral therapy (ART) regimen or who were continuing enrollees in the ATLAS study (one third had completed 52 weeks); all were receiving therapy and virally suppressed for ≥6 months with no history of virologi…